The Latin America, Middle East and Africa In Vitro Toxicity Testing Market is expected to witness market growth of 13.9% CAGR during the forecast period (2022-2028).
In-vitro toxicology tests for evaluating drug product safety, along with the evaluation of the possible effect of medicines on cells and tissues, are expected to boost revenue growth in the market. Companies have diversified their portfolios to meet competition in the market for in-vitro toxicology testing, as the demand for such tests has grown.
Even though the in vitro toxicity business is relatively new, it has a lot of potential for further development. This industry is expected to be dominated by technological advancements and the introduction of new products. The absence of pharmaceutical powerhouses in this sector provides a better opportunity for newcomers to position themselves in the market. As a result, a corporation planning to spend can enter this expanding market and be successful, as the market has a lot of room for new competitors.
In Brazil the Guidance for Safety Assessment of Cosmetic Products has been updated to provide criteria for evaluating the safety of cosmetics sold in Brazil as well as information on testing methods. The Guideline does not mandate any specific test for skin sensitivity assessment, however, it does recommend the LLNA. The GPMT, the Buehler test, and clinical studies like the human repeat shock physical exam are all covered.
In Brazil, a risk evaluation is required before cosmetic compounds can be classified as skin sensitizers or nonsensitizers. Alternative approaches are accepted, subject to the limits of each technique and their regulatory implications. In silico methodologies, such as structure-activity relationships, are, for example, accepted when utilized as a part of integrated testing and assessment procedures.
The UAE government wants to enhance healthcare funding so that more data monitoring tools can be used for proactive COVID contact tracking and virtual healthcare service providers can be licensed. The government also intends to strengthen national capacities to combat future pandemics, including initiatives to create vaccines and medications, as well as digital immunization IDs and a new supply chain strategy. The Ministry of Health wants to grow the sector by putting more emphasis on health information technology, such as telehealth and digital medicine.
The Brazil market dominated the LAMEA In Vitro Toxicity Testing Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $763.1 Million by 2028. The Argentina market is poised to grow at a CAGR of 14.5% during (2022-2028). Additionally, The UAE market is expected to display a CAGR of 13.6% during (2022-2028).
Based on Type, the market is segmented into Absorption, Toxic Substances, and Dose. Based on Technology, the market is segmented into Cell Culture Technologies, High Throughput Technologies, and Toxicogenomics. Based on End User, the market is segmented into Cosmetics & Households Products, Pharmaceuticals Industry, Food Industry, Chemicals, and Industry. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., General Electric (GE) Co., AstraZeneca PLC, Catalent, Inc., Laboratory Corporation of America Holdings, Acacia Pharma Group Plc, GlaxoSmithKline PLC, Helsinn Healthcare SA., and Heron Therapeutics, Inc.
By Type
By Country
In-vitro toxicology tests for evaluating drug product safety, along with the evaluation of the possible effect of medicines on cells and tissues, are expected to boost revenue growth in the market. Companies have diversified their portfolios to meet competition in the market for in-vitro toxicology testing, as the demand for such tests has grown.
Even though the in vitro toxicity business is relatively new, it has a lot of potential for further development. This industry is expected to be dominated by technological advancements and the introduction of new products. The absence of pharmaceutical powerhouses in this sector provides a better opportunity for newcomers to position themselves in the market. As a result, a corporation planning to spend can enter this expanding market and be successful, as the market has a lot of room for new competitors.
In Brazil the Guidance for Safety Assessment of Cosmetic Products has been updated to provide criteria for evaluating the safety of cosmetics sold in Brazil as well as information on testing methods. The Guideline does not mandate any specific test for skin sensitivity assessment, however, it does recommend the LLNA. The GPMT, the Buehler test, and clinical studies like the human repeat shock physical exam are all covered.
In Brazil, a risk evaluation is required before cosmetic compounds can be classified as skin sensitizers or nonsensitizers. Alternative approaches are accepted, subject to the limits of each technique and their regulatory implications. In silico methodologies, such as structure-activity relationships, are, for example, accepted when utilized as a part of integrated testing and assessment procedures.
The UAE government wants to enhance healthcare funding so that more data monitoring tools can be used for proactive COVID contact tracking and virtual healthcare service providers can be licensed. The government also intends to strengthen national capacities to combat future pandemics, including initiatives to create vaccines and medications, as well as digital immunization IDs and a new supply chain strategy. The Ministry of Health wants to grow the sector by putting more emphasis on health information technology, such as telehealth and digital medicine.
The Brazil market dominated the LAMEA In Vitro Toxicity Testing Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $763.1 Million by 2028. The Argentina market is poised to grow at a CAGR of 14.5% during (2022-2028). Additionally, The UAE market is expected to display a CAGR of 13.6% during (2022-2028).
Based on Type, the market is segmented into Absorption, Toxic Substances, and Dose. Based on Technology, the market is segmented into Cell Culture Technologies, High Throughput Technologies, and Toxicogenomics. Based on End User, the market is segmented into Cosmetics & Households Products, Pharmaceuticals Industry, Food Industry, Chemicals, and Industry. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., General Electric (GE) Co., AstraZeneca PLC, Catalent, Inc., Laboratory Corporation of America Holdings, Acacia Pharma Group Plc, GlaxoSmithKline PLC, Helsinn Healthcare SA., and Heron Therapeutics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Absorption
- Toxic Substances
- Dose
- Cell Culture Technologies
- High Throughput Technologies
- Toxicogenomics
- Cosmetics & Households Products
- Pharmaceuticals Industry
- Food Industry
- Chemicals Industry
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc.
- General Electric (GE) Co.
- AstraZeneca PLC
- Catalent, Inc.
- Laboratory Corporation of America Holdings
- Acacia Pharma Group Plc
- GlaxoSmithKline PLC
- Helsinn Healthcare SA.
- Heron Therapeutics, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA In Vitro Toxicity Testing Market by Type
Chapter 4. LAMEA In Vitro Toxicity Testing Market by Technology
Chapter 5. LAMEA In Vitro Toxicity Testing Market by End User
Chapter 6. LAMEA In Vitro Toxicity Testing Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- General Electric (GE) Co.
- AstraZeneca PLC
- Catalent, Inc.
- Laboratory Corporation of America Holdings
- Acacia Pharma Group Plc
- GlaxoSmithKline PLC
- Helsinn Healthcare SA.
- Heron Therapeutics, Inc.
Methodology
LOADING...
